ArticleFrontiers in oncology2026
Case Report: Diabetic ketoacidosis following EGFR-TKIs therapy via aggravated insulin resistance.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an established first-line treatment for non-small cell lung cancer (NSCLC) patients with sensitizing mutations because of their remarkable efficacy and favorable tolerability profiles. However, rare and severe adverse reactions during their application require attention. Cases of diabetic ketoacidosis (DKA) associated with EGFR-TKI therapy have seldom been reported and the underlying mechanism remains unclear. Case presentation: We present the case of a 64-year-old female patient with immune checkpoint inhibitor-induced diabetes mellitus (ICI-DM) on aumolertinib (a third-generation EGFR-TKI, 110 mg daily) for the treatment of NSCLC admitted to the hospital with frequent episodes of DKA. Owing to a recurrent DKA episode following a reduced dosage (55 mg daily), aumolertinib was suspended permanently. After full recovery from the DKA, the patient was switched to osimertinib (80 mg daily). Insulin resistance in the patient was assessed using a hyperinsulinemic-euglycemic clamp. She was maintained on standard-dose osimertinib and insulin therapy after discharge and remained asymptomatic during the outpatient follow-up. Conclusion: Owing to the protocol-defined strict inclusion and exclusion criteria, some potentially serious adverse reactions may not be as commonly observed in clinical trial settings. Aumolertinib-induced exacerbation of insulin resistance can precipitate a spectrum of hyperglycemia, ranging from mild elevations to severe DKA, which highlights the necessity of blood glucose monitoring throughout the treatment course. By assessing a patient's tolerance profile for EGFR-TKIs-aggravated insulin resistance using the insulin clamp technique, clinicians can optimize antineoplastic regimens, such as switching from aumolertinib to osimertinib in this case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.